Last $38.28 USD
Change Today +0.14 / 0.37%
Volume 108.3K
ANIK On Other Exchanges
As of 3:28 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

anika therapeutics inc (ANIK) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/26/14 - $52.49
52 Week Low
02/5/14 - $28.79
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

anika therapeutics inc (ANIK) Related Businessweek News

No Related Businessweek News Found

anika therapeutics inc (ANIK) Details

Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company’s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee and joints; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells that is used in connection with soft tissue regeneration; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company’s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise Hyalobarrier, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product for the prevention of spinal post-surgical adhesions; Merogel, a woven fleece nasal packin; and Merogel Injectable, a viscous hydrogel. The company’s ophthalmic products include AMVISC, AMVISC Plus, STAARVISC-II, Optivisc, AnikaVisc, and AnikaVisc Plus that are injectable HA products used as viscoelastic agents in ophthalmic surgical procedures, including cataract extraction and intraocular lens implantation; and veterinary product comprise HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. markets its products through a network of distributors. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

102 Employees
Last Reported Date: 03/13/14
Founded in 1983

anika therapeutics inc (ANIK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $400.9K
Chief Operating Officer
Total Annual Compensation: $286.8K
Compensation as of Fiscal Year 2013.

anika therapeutics inc (ANIK) Key Developments

Anika Therapeutics Inc. Provides Revenue Guidance for the Fourth Quarter of 2014

Anika Therapeutics Inc. provided revenue guidance for the fourth quarter of 2014. For the period, the company expects continued growth in viscosupplementation patient demand in US market, and expects its product revenue to grow faster than the market growth rate. At the same time, revenue for the fourth quarter is expected to fall short of its internal expectations due to partner ordering patterns and weaker than expected international sales. The potential assignment of a unique J-Code for Monovisc from CMS and its related milestone payment, does however, provide revenue upside.

Anika Therapeutics Inc. Announces Executive Appointments

On October 30, 2014, Anika Therapeutics Inc. announced the appointment of Edward S. Ahn, Ph.D., 42, as its Chief Technology and Strategy Officer, effective immediately. From June 2012 through the present, Dr. Ahn was Managing Director and Chief Science Officer at MedCap Advisors where he built merger strategies, strategic partnerships and licensing agreements for emerging medical device, biotechnology and biological organizations with a focus on regenerative medicine. On October 30, 2014, the company also announced the appointment of Frank J. Luppino, 46, as its Chief Operating Officer, effective immediately. From 2013 through the present, Mr. Luppino provided strategic consulting services and leadership on key project efforts to a number of pharmaceutical and medical device companies including Anika Therapeutics Inc. Effective October 28, 2014, the employment of John W. Sheets Jr., Ph.D., as Chief Scientific Officer of the company has ended. Effective October 29, 2014, the employment of Carol A. Barnett as Chief Commercial Officer of the company has ended.

Anika Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Anika Therapeutics Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $22,055,423 against $17,754,438 a year ago. Income from operations was $10,286,218 against $7,766,273 a year ago. Income before income taxes was $10,296,155 against $7,733,457 a year ago. Net income was $6,170,800 or $0.40 per diluted share against $4,957,258 or $0.33 per diluted share a year ago. Operating income was $10.3 million, up 32% from $7.8 million in the third quarter of 2013. For the nine months, the company reported total revenue of $82,340,370 against $53,829,826 a year ago. Income from operations was $49,359,499 against $22,176,189 a year ago. Income before income taxes was $49,375,838 against $22,067,434 a year ago. Net income was $30,503,403 or $1.97 per diluted share against $13,920,152 or $0.95 per diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANIK:US $38.28 USD +0.14

ANIK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Iridex Corp $8.75 USD -0.0614
STAAR Surgical Co $9.29 USD +0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation ANIK Industry Range
Price/Earnings 15.8x
Price/Sales 5.4x
Price/Book 3.3x
Price/Cash Flow 14.9x
TEV/Sales 4.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANIKA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at